Clinical trials: insulin glargine, open to volunteers
Type 2 Diabetes
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
The purpose of this study is to evaluate efficacy and safety of SHR-3167 versus Insulin glargine in insulin-naive type 2 diabetes inadequately controlled on non-insulin anti-diabetic drugs.
- Trial name
- NCT07920939
- Testing
- SHR-3167 Injection, Insulin glargine (IGlar)
- Where
- 2 sites in China
- Volunteers
- 450 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM)
RCT Glargine vs NPH for Treatment of DM in Pregnancy
We are asking you to take part in this research study because you are diagnosed with pregestational Type 2 Diabetes Mellitus or Gestational Diabetes Mellitus requiring insulin therapy in pregnancy.
- Conditions
- Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM), Gestational Diabetes Mellitus, Class A2
- Trial name
- NCT06619301
- Testing
- Insulin glargine, insulin NPH
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Loyola University
Pregestational Diabetes, Pregnancy
Once-Daily vs Twice-Daily Insulin Glargine in Pregestational Diabetes Management
The purpose of this study is to determine if taking insulin glargine twice a day instead of once a day will better manage pregestational diabetes in pregnant patients.
- Trial name
- NCT07224893
- Testing
- Use of insulin glargine once daily, Use of insulin glargine twice daily
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Eastern Virginia Medical School
Type 2 Diabetes Patients, Overweight and Obesity
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
The present 24-week, prospective, open-label, randomized, multicenter, parallel group trial is carried to investigate and evaluate the efficacy and safety of Liraglutide in combination with prandial insulin therapy vs insulin…
- Conditions
- Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)
- Trial name
- LiraGooD (NCT03087032)
- Testing
- Liraglutide, insulin glargine
- Where
- China
- Volunteers
- 164 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Gestational Diabetes, Pregnancy Related
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes
The aim of our study is to compare neonatal and maternal outcomes using different thresholds for the initiation and titration of pharmacotherapy for gestational diabetes (GDM).
- Trial name
- START 1 (NCT06419777)
- Testing
- Insulin
- Where
- 2 sites in United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Gestational Diabetes Mellitus, Pregnancy, High Risk
DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes
This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 individuals with gestational…
- Trial name
- DECIDE (NCT06445946)
- Testing
- Metformin, Insulin
- Where
- 26 sites in United States
- Volunteers
- 1,572 people
- Sponsor
- Ohio State University
Type 1 Diabetes Mellitus
Insulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic Control in Type 1 Diabetic Patients
The transition from the Pediatric clinic to the adult care is a challenging period for young adults with type 1 diabetes, due to the high risk of poor glycemic control.
- Trial name
- METRO (NCT03463564)
- Testing
- Insulin pump, Insulin injections
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- University of Campania Luigi Vanvitelli
Type 2 Diabetes, Cardiovascular Risk
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already…
- Trial name
- AMBITION 7 (NCT07797335)
- Testing
- Zenagamtide, Insulin glargine U-100
- Where
- 330 sites in United States, Argentina and 14 more
- Volunteers
- 1,778 people
- Sponsor
- Novo Nordisk A/S
Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes
Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes
Objectives: The primary objective is to assess the safety and tolerability of medical drugs with the potential to enhance performance (PES) in professional athletes over a 5.5 year period, encompassing a 25-week PES Exposure…
- Trial name
- ASCEND001 (NCT07568574)
- Testing
- Testosterone Enanthate, Testosterone Cypionate, Testosterone Propionate
- Where
- United Arab Emirates
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Enhanced Emirates Limited
Steroid-Induced Diabetes, Steroid-Induced Hyperglycemia
Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes
Glucocorticoids are commonly used in the treatment of autoimmune, inflammatory, and neoplastic diseases. Despite their therapeutic efficacy, they are associated with significant metabolic side effects.
- Conditions
- Steroid-Induced Diabetes, Steroid-Induced Hyperglycemia, Diabetes
- Trial name
- NCT07117240
- Testing
- lixisenatide + glargine, Intensive insulin therapy
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Warsaw
Sudden Sensorineural Hearing Loss (SSNHL), Prediabetes / Type 2 Diabetes
CGM-guided Patch Pump vs Basal-Bolus Injection for Steroid-Induced Hyperglycemia in Sudden Sensorineural Hearing Loss: SHIP Trial
This exploratory randomized controlled trial evaluates whether a CGM-guided temporary patch pump (CareLevo CSII) reduces glucocorticoid-induced hyperglycemia (GIH) compared to a Lantus-based basal-bolus injection (MDI) regimen in…
- Trial name
- SHIP (NCT07652528)
- Testing
- CareLevo Patch-type Insulin Pump, Insulin Glargine U-100 (Lantus), Fast-acting Insulin Aspart (Fiasp)
- Volunteers
- 50 people
- Sponsor
- Hallym University
Type 2 Diabetes (T2D)
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
This study is an open-label, 1:1 randomized, active-controlled, 2-arm, 20-week treatment duration, parallel-group, multicenter, phase IV study to evaluate the effect of iGlarLixi versus Gla-100 on glycemic control measured as TIR…
- Trial name
- China Soli-CGM (NCT06671587)
- Testing
- iGlarLixi (insulin glargine/lixisenatide), Gla-100 (insulin glargine)
- Where
- China
- Volunteers
- 678 people
- Sponsor
- Sanofi
Type 2 Diabetes
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
Failure of oral antidiabetic drugs (OADs) is a frequent challenge in patients with type 2 diabetes mellitus (T2DM), and inadequate long-term glycemic control substantially increases the risk of diabetic complications.
- Trial name
- NCT07173712
- Testing
- CSII, Insulin glargine /lixisenatide Fixed Ratio Combination, Insulin Degludec and Insulin Aspart Injection
- Volunteers
- 324 people
- Sponsor
- Yanbing Li
Type 2 Diabetes Mellitus
Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes
The effects of Tirzepatide and Insulin Glargine on glucose and lipid metabolism and inflammation in patients with type 2 diabetes mellitus.
- Trial name
- NCT05553093
- Testing
- Tirzepatide, Insulin Glargine
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Type 2 Diabetes
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
This study is a prospective, open-label, multicenter, parallel-group, positive-controlled, and pragmatic randomized clinical trial (pRCT).
- Trial name
- NCT07307235
- Testing
- iGlarLixi (insulin glargine/lixisenatide), standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs)
- Where
- 24 sites in China
- Volunteers
- 1,316 people
- Sponsor
- Shanghai Zhongshan Hospital
Gestational Diabetes, Pregnancy Related
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)
The aim of our study is to compare neonatal and maternal outcomes using different thresholds for the initiation and titration of pharmacotherapy for gestational diabetes (GDM).
- Trial name
- START2 (NCT06419803)
- Testing
- Insulin
- Where
- 2 sites in United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Diabetes in Pregnancy, Gestational Diabetes
Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)
The goal of this clinical trial is to see if diabetes in pregnancy can be treated with once daily dosing of insulin instead of once daily dosing plus insulin with meals. The main question this study aims to answer is: 1.
- Trial name
- SUGAR (NCT07171684)
- Testing
- Insulin glargine alone, Insulin glargine + insulin lispro
- Where
- 2 sites in United States
- Volunteers
- 176 people
- Sponsor
- Rutgers, The State University of New Jersey
Diabetes Mellitus
Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in Diabetic Tunisian Patients.
This study will have a single arm: the patient on NPH will continue his treatment for 4 weeks, at the end of the NPH treatment, the patient will receive his CGM device for three days for glycemic holter, a switch to insulin…
- Trial name
- GRANT (NCT06999551)
- Testing
- switch NPH to glargin
- Where
- Tunisia
- Volunteers
- 60 people
- Sponsor
- Les Laboratoires des Médicaments Stériles